Lantern Pharma Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00GM6LK17
LTRN
Lantern Pharma Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Lantern Pharma Inc.
ISIN
US51654W1018
TICKER
LTRN
MIC
XNAS
REUTERS
LTRN.OQ
BLOOMBERG
LTRN US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Do., 07.11.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending Septemb...
Lantern Pharma
Di., 05.11.2024
Lantern Pharma
US51654W1018
Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight...
Lantern Pharma
Do., 31.10.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thu...
Lantern Pharma
Mi., 23.10.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at t...
Lantern Pharma
Mo., 21.10.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that they will be participating in and hosting two webinars that are open to the public during October.
Lantern expects to di...
Lantern Pharma
Di., 15.10.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-...
Lantern Pharma
Mo., 23.09.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, announced today that the company has been granted three rare pediatric disease designations (RPDD) by t...
Lantern Pharma
Do., 08.08.2024
Lantern Pharma
US51654W1018
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the second quarter 2024, ending June 3...
Lantern Pharma
Informationen zu Product Placements
